Skip to main content

Jacques Planas Morin

Institutions of which they are part

Biomedical Research in Urology
Vall Hebron Institut de Recerca

Research lines

Hormone therapy and castrate resistant prostate cancer (Clinical research)

One main objective is the optimization of androgen suppression and to know its safety profile, specifically in the areas of bone mass loss, the metabolic disturbances and cognitive performance. How to perform early diagnosis of CRPC, and how to follow up the new treatments are also objectives of this line.

IP: Jacques Planas Morin

Projects

Nuevas estrategias para la mejora del diagnóstico y el manejo terapéutico de los portadores de mutaciones en BRCA2

IP: Anna Santamaria Margalef
Collaborators: Leticia Suarez Cabrera, Marta Barber Servera, Adrian Garcia Rodriguez, Mercè Cuadras Solé, Jacques Planas Morin
Funding agency: Instituto de Salud Carlos III
Funding: 159720
Reference: PI21/00977
Duration: 01/01/2022 - 31/12/2024

Radiogenomics for the prediction of prostate cancer aggressiveness through artificial intelligence.

IP: Joan Morote Robles
Collaborators: Leticia Suarez Cabrera, Inés de Torres Ramirez, Marta Barber Servera, Ana Celma Domènech, Adrian Garcia Rodriguez, Jacques Planas Morin, Richard Mast
Funding agency: Instituto de Salud Carlos III
Funding: 159720
Reference: PI20/01666
Duration: 01/01/2021 - 31/12/2023

Detección temprana de recurrencia para una terapia personalizada en pacientes hormono-sensibles con cáncer de próstata metastásico.

IP: Rosanna Paciucci Barzanti
Collaborators: Luisa Maria Martinez Sánchez, Jacques Planas Morin
Funding agency: Ministerio Economía, Industria y Competitividad
Funding: 108900
Reference: RTI2018-096055-B-I00
Duration: 01/01/2019 - 30/09/2022

El estrés terapeútico como generador de resistencia en las células madre neoplásicas prostáticas: marcadores predictivos de resistencia y dianas terapéuticas

IP: Rosanna Paciucci Barzanti
Collaborators: Inés de Torres Ramirez, Jacques Planas Morin
Funding agency: Ministerio Economía, Industria y Competitividad
Funding: 181500
Reference: SAF2014-59958-R
Duration: 01/01/2015 - 31/12/2017

Related news

On World Cancer Research Day, we highlight the impact of VHIR projects in the field of oncology.

The drug EB1 is able to block resistance pathways to standard cancer treatments and could increase the efficacy of chemotherapy or immunotherapy.

Durant el mes de juny, organitzem tres activitats sobre assaigs clínics, genètica i imatges científiques.

Related professionals

Jacques Planas Morin

Jacques Planas Morin

Biomedical Research in Urology
Read more
Richard Mast

Richard Mast

Read more
David Ruiz Casajuana

David Ruiz Casajuana

Research technician
Biomedical Research in Urology
Read more
Leticia Suarez Cabrera

Leticia Suarez Cabrera

Predoctoral researcher
Biomedical Research in Urology
Read more

Subscriu-te als nostres butlletíns i forma part de la vida del Campus

El Vall d’Hebron Barcelona Hospital Campus és un parc sanitari de referència mundial on assistència, recerca, docència i innovació es donen la mà.